Cargando…
Americas’ opioid/psychostimulant epidemic would benefit from general population early identification of genetic addiction risk especially in children of alcoholics (COAs)
Autores principales: | Blum, K, Baron, D, Hauser, M, Henriksen, S, Thanos, PK, Black, C, Siwicki, D, Modestino, EJ, Downs, BW, Badgaiyan, S, Simpatico, TA, Boyett, B, Badgaiyan, RD |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7032561/ https://www.ncbi.nlm.nih.gov/pubmed/32082617 |
Ejemplares similares
-
Would induction of dopamine homeostasis via coupling genetic addiction risk score (GARS®) and pro-dopamine regulation benefit benzodiazepine use disorder (BUD)?
por: Blum, K, et al.
Publicado: (2018) -
Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD)
por: Blum, K, et al.
Publicado: (2019) -
Addiction by Any Other Name is Still Addiction: Embracing Molecular Neurogenetic/Epigenetic Basis of Reward Deficiency
por: Edwards, Drew, et al.
Publicado: (2020) -
A Novel Precision Approach to Overcome the “Addiction Pandemic” by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration
por: Blum, Kenneth, et al.
Publicado: (2021) -
Can We Combat Reward Deficiency Behaviors (RDS) including Substance Use Disorder (SUD) through Genetic Risk Screening coupled with Precision Pro-Dopamine Regulation by Algorithmic matched Polymorphic Allelic Risks
por: Blum, Kenneth, et al.
Publicado: (2019)